Merck & Co., Inc. (MRK)
| Market Cap | 249.17B |
| Revenue (ttm) | 63.17B |
| Net Income (ttm) | 12.15B |
| Shares Out | 2.53B |
| EPS (ttm) | 4.78 |
| PE Ratio | 20.61 |
| Forward PE | 10.80 |
| Dividend | $3.08 (3.13%) |
| Ex-Dividend Date | Sep 16, 2024 |
| Volume | 8,824,071 |
| Open | 98.51 |
| Previous Close | 98.58 |
| Day's Range | 97.90 - 99.45 |
| 52-Week Range | 97.90 - 134.63 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 130.86 (+32.85%) |
| Earnings Date | Oct 31, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $130.86, which is an increase of 32.85% from the latest price.
News
Merck to Participate in the Jefferies London Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,.
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By...
Merck signs $3.3 bln deal for experimental cancer drug
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today...
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinic...
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs.
Merck: An Undervalued Dividend Machine
Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the onc...
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared t...
Merck to Participate in the UBS Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the UBS Global Healthcare Conference.
Top 2 pharma stocks to buy amid surge in deadly fungi
Recent data cited by Bloomberg reveals that deadly fungi, including Candida auris, have been spreading globally since the COVID-19 pandemic. Climate change has enabled many of these illness-causing ag...
Investing Groups Digest: Mag 7 In The Market Spotlight
Seeking Alpha's Investing Group leaders presented their earnings assessments from Mag 7 tech giants. Are investors missing hidden opportunities with BDCs, CEFs, mREITs, and preferreds? The case is mad...
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.
Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript
Start Time: 09:00 January 1, 0000 10:00 AM ET Merck & Co., Inc. (NYSE:MRK) Q3 2024 Earnings Call October 31, 2024, 09:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and...
Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year
Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, rece...
Merck tops earnings estimates on strong demand for Keytruda even as HPV vaccine sales fall
CNBC's Becky Quick reports on the company's quarterly earnings results.
Merck's Q3 earnings beat estimates, but company lowers guidance
Merck's stock swung between gains and losses in premarket action.
Merck third quarter better than expected, but Gardasil sales sag in China again
Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the U.S. drugmaker also flagged a second straight quarter of...
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal...
Merck Announces Third-Quarter 2024 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2024 Financial Results.
Merck's Earnings Need to Reassure Investors That All Is Well
The drug company had a disastrous second quarter. It doesn't want a repeat performance.
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiatio...
BetterInvesting™ Magazine Update on Merck (MRK) and Ball (BALL)
TROY, Mich. , Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE: MRK) as its "Stock to Study" and Ball ...
3-Stock Lunch: Merck, Ecolab & Xylem Inc
Anthony Forcione, Rockland Trust vice president, joins 'Power Lunch' to discuss stock plays for three stocks.
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key drugs Ga...